Raynaud's phenomenon as a manifestation of parvovirus B19 infection: Case reports and review of parvovirus B19 rheumatic and vasculitic syndromes

Clinical Infectious Diseases

Volumn 30, Issue 3, 2000, Pages 500-503

  Harel, Liora ^a   Straussberg, Rachel ^a   Rudich, Hagit ^b   Cohen, Avner H ^c   Amir, Jacob ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c Pediatric Emergency Department   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTHRALGIA; ARTHROPATHY; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; ERYTHEMA INFECTIOSUM; FEMALE; FETUS HYDROPS; HUMAN; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RHEUMATIC DISEASE; SYMPTOMATOLOGY; VASCULITIS;

ADOLESCENT; ANTIBODIES, VIRAL; ERYTHEMA INFECTIOSUM; FEMALE; HUMANS; PARVOVIRUS B19, HUMAN; RAYNAUD DISEASE; RHEUMATIC DISEASES; SYNDROME; VASCULITIS;

EID: 0034128557     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313712     Document Type: Article

References (46)

1. 1. Portmore AC. Parvoviruses (erythema infectiosum, aplastic crisis). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:1439-46.
2. 2. Schwarz TF, Modrow S, Hottentrager B, et al. New oligopeptide immunoglobulin G test for human parvovirus B19 antibodies. J Clin Microbiol 1991;29:431-5.
3. 3. Fridell E, Cohen BJ, Wahren B. Evaluation of a synthetic-peptide enzyme-linked immunosorbent assay for immunoglobulin M to human parvovirus B19. J Clin Microbiol 1991;29:1376-81.
4. 4. Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998;24:375-401.
5. 5. Semble EL, Agudelo CA. Pegram PS. Human parvovirus B19 arthropathy in two adults after contact with childhood erythema infectiosum. Am J Med 1987;83:560-2.
6. 6. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989;149:1153-6.
7. 7. Klouda PT, Corbin SA, Bradley BA, Cohen BJ, Woolf AD. HLA and acute arthritis following human parvovirus infection. Tissue Antigens 1986;28: 318-9.
8. 8. White DG, Mortimer PP, Blake DR, Woolf AD, Cohen BJ, Bacon PA. Human parvovirus arthropathy. Lancet 1985;1:419-21.
9. 9. Smith CA, Woolf AD, Lenci M. Parvoviruses: infections and arthropathies. Rheum Dis Clin North Am 1987;13:249-63.
10. 10. Stoll T, Bruhlmann P, Brunner U, Treier A, Cassinotti P, Michel BA. Parvovirus-B19-induced arthritis/arthropathy and ils importance in differential diagnosis of rheumatoid arthritis. Schweiz Med Wochenschr 1995;125:347-54.
11. 11. Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:8227-32.
12. 12. Naides SJ, Field EH. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med 1988;148:2587-9.
13. 13. Sasaki T, Takahashi Y, Yoshinaga K, Sugamura K, Shiraishi H. An association between human parvovirus B-19 infection and autoantibody production [letter]. J Rheumatol 1989;16:708-9.
14. 14. Woolf AD, Campion GV, Klouda PT, et al. HLA and the manifestations of human parvovius B19 infection. Arthritis Rheum Dis 1987;30:52.
15. 15. Hajeer AH, MacGregor AJ, Rigby AS, Ollier WE, Carth D, Silman AJ. Influence of previous exposure to human parvovirus B19 infection in explaining susceptibility to rheumatoid arthritis: an analysis of disease discordant twin pairs. Ann Rheum Dis 1994;53:137-9.
16. 16. Nikkari S, Luukkainen R, Mottonen T, et al. Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994;53:106-11.
17. 17. Nikkari S, Roivainen A, Hannonen P, et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995;54:597-600.
18. 18. Nikkari S, Toivanen P. Parvovirus B19 in rheumatoid arthritis: comment on the article by Kerr et al. [letter]. Br J Rheumatol 1996;35:49.
19. 19. Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992;12:147-51.
20. 20. Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. J Pediatr 1993;122:186-90.
21. 21. Rivier G, Gerster JC, Terrier P, Cheseaux J-J. Parvovirus B19 associated monoarthritis in a 5-year-old boy. J Rheumatol 1995;22:766-7.
22. 22. Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum 1991;34:1319.
23. 23. Jawad AS. Lupus and parvovirus. Br J Rheumatol 1993;32:527-8.
24. 24. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol 1992;99:566-74.
25. 25. Cooper CL, Choudhri SH. Diagnosis: leukocytoclastic vasculitis secondary to parvovirus B19 infection [photo quiz]. Clin Infect Dis 1998;26:849, 989.
26. 26. Lefrere J-J, Courouce AM, Soulier JP, et al. Henoch-Schönlein purpura and human parvovirus infection. Pediatrics 1986;78:183-4.
27. 27. Lefrere J-J, Courouce A-M, Kaplan C. Parvovirus and idopathic thrombo cytopenic purpura [letter]. Lancet 1989;1:279.
28. 28. Nikkari S, Mertsola J, Korvenranta H, Vainionpaa R, Toivanen P. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994;37: 1707-10.
29. 29. Corman LC, Staud R. Association of Wegener's granulomatosis with parvovirus B19 infection: comment on the concise communication by Nikkari et al. [letter]. Arthritis Rheum 1995;38:1174-5.
30. 30. Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994;343:1255-8.
31. 31. Zulian F, Costantini C, Montesco MC, Schiavon F, Zacchello F. Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost. Br J Rheumatol 1998;37:228-30.
32. 32. Li Loong TC, Coyle PV, Anderson MJ, Allen GE, Connolly JH. Human serum parvovirus associated vasculitis. Postgrad Med J 1986;62:493-4.
33. 33. Corman LC, Dolson DJ. Polyarteritis nodosa and parvovirus B19 infection. Lancet 1992;339:491.
34. 34. Stone MS, Murph JR. Papular-purpuric gloves and socks syndrome: a characteristic viral exanthem. Pediatrics 1993;92:864-5.
35. 35. Nigro G, Zerbini M, Krzysztofiak A, et al. Active or recent parvovirus B19 infection in children with Kawasaki disease. Lancet 1994;343:1260-1.
36. 36. Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity and possible onset of systemic lupus erythematosus. J Rheumatol 1996;23:1180-5.
37. 37. Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus associated arthritis: a clinical and laboratory description. Lancet 1985;1: 422-5.
38. 38. Joseph PR. Fifth disease: the frequency of joint involvement in adults. NY State J Med 1986;86:560-3.
39. 39. Ager EA, Chin TDY, Poland JD. Epidemic erythema infectiosum. N Engl J Med 1966;275:1326-31.
40. 40. Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults: initial two year clinical experience. Arthritis Rheum 1990;33:1297-309.
41. 41. Longo G, Luppi M, Bertesi M, Ferrara L, Torelli G, Emilia G. Still's disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection. Clin Infect Dis 1998;26:994-5.
42. 42. Anderson LJ. Human parvoviruses. J Infect Dis 1990;161:603-8.
43. 43. Vigeant P, Menard H-A, Boire G. Chronic modulation of the autoimmune response following parvovirus B19 infection. J Rheumatol 1994;21: 1165-7.
44. 44. Halasz CLG, Cormier D, Den M. Petechial glove and sock syndrome caused by parvovirus B19. J Am Acad Dermatol 1992;27:835-8.
45. 45. Smith PT, Landry ML, Carey H, Krasnoff J, Cooney E. Papular-purpuric gloves and socks syndrome associated with acute parvovirus B19 infection: case report and review. Clin Infect Dis 1998;27:164-8.
46. 46. Seibold JR. Scleroderma. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders, 1993: 1119-22.